MNKD – MannKind Corporation
MannKind CorporationMNKD
$4.54Name : MannKind Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,379,506,176.00
EPSttm : 0.1
MannKind Corporation
$4.54
0.22%$0.01Float Short %
9.69
Margin Of Safety %
58
Put/Call OI Ratio
0.06
EPS Next Q Diff
0.04
EPS Last/This Y
0.17
EPS This/Next Y
0.05
Price
4.54
Target Price
10.25
Analyst Recom
1
Performance Q
-24.46
Relative Volume
0.67
Beta
1.17
Ticker: MNKD
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-21 | MNKD | 5.22 | 0.09 | 0.03 | 50451 |
| 2025-03-24 | MNKD | 5.22 | 0.09 | 0.19 | 47971 |
| 2025-03-25 | MNKD | 5.23 | 0.09 | 0.10 | 48581 |
| 2025-03-26 | MNKD | 5.05 | 0.09 | 0.08 | 48626 |
| 2025-03-27 | MNKD | 5.1 | 0.08 | 0.01 | 48985 |
| 2025-03-28 | MNKD | 5.04 | 0.07 | 0.02 | 48777 |
| 2025-03-31 | MNKD | 5.04 | 0.07 | 0.73 | 49256 |
| 2025-04-01 | MNKD | 4.94 | 0.07 | 0.00 | 50088 |
| 2025-04-02 | MNKD | 5.01 | 0.07 | 0.00 | 50130 |
| 2025-04-03 | MNKD | 4.88 | 0.07 | 4.31 | 50138 |
| 2025-04-04 | MNKD | 4.74 | 0.07 | 0.00 | 50121 |
| 2025-04-07 | MNKD | 4.69 | 0.07 | 0.01 | 50038 |
| 2025-04-08 | MNKD | 4.64 | 0.07 | 0.33 | 51809 |
| 2025-04-09 | MNKD | 4.7 | 0.07 | 0.02 | 51828 |
| 2025-04-10 | MNKD | 4.65 | 0.06 | 0.10 | 52946 |
| 2025-04-11 | MNKD | 4.6 | 0.06 | 0.00 | 53300 |
| 2025-04-14 | MNKD | 4.62 | 0.06 | 0.01 | 54458 |
| 2025-04-15 | MNKD | 4.64 | 0.06 | 0.01 | 54808 |
| 2025-04-16 | MNKD | 4.53 | 0.06 | 0.02 | 54858 |
| 2025-04-17 | MNKD | 4.53 | 0.06 | 0.07 | 55082 |
| 2025-04-18 | MNKD | 4.54 | 0.06 | 0.06 | 55082 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-21 | MNKD | 5.22 | - | - | 0.17 |
| 2025-03-24 | MNKD | 5.23 | - | - | 0.17 |
| 2025-03-25 | MNKD | 5.22 | - | - | 0.17 |
| 2025-03-26 | MNKD | 5.06 | - | - | 0.17 |
| 2025-03-27 | MNKD | 5.10 | - | - | 0.17 |
| 2025-03-28 | MNKD | 5.03 | - | - | 0.17 |
| 2025-03-31 | MNKD | 5.03 | - | - | 0.17 |
| 2025-04-01 | MNKD | 4.95 | - | - | 0.17 |
| 2025-04-02 | MNKD | 5.02 | - | - | 0.17 |
| 2025-04-03 | MNKD | 4.88 | - | - | 0.17 |
| 2025-04-04 | MNKD | 4.73 | - | - | 0.17 |
| 2025-04-07 | MNKD | 4.69 | - | - | 0.17 |
| 2025-04-08 | MNKD | 4.62 | - | - | 0.17 |
| 2025-04-09 | MNKD | 4.70 | - | - | 0.17 |
| 2025-04-10 | MNKD | 4.65 | - | - | 0.17 |
| 2025-04-11 | MNKD | 4.66 | - | - | 0.27 |
| 2025-04-14 | MNKD | 4.63 | - | - | 0.27 |
| 2025-04-15 | MNKD | 4.64 | - | - | 0.27 |
| 2025-04-16 | MNKD | 4.53 | - | - | 0.27 |
| 2025-04-17 | MNKD | 4.54 | - | - | 0.27 |
| 2025-04-18 | MNKD | 4.54 | - | - | 0.27 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-21 | MNKD | -2.32 | 9.04 | 9.85 |
| 2025-03-24 | MNKD | -2.32 | 9.20 | 9.85 |
| 2025-03-25 | MNKD | -2.32 | 9.20 | 9.85 |
| 2025-03-26 | MNKD | -2.32 | 9.20 | 9.67 |
| 2025-03-27 | MNKD | -2.32 | 9.20 | 9.67 |
| 2025-03-28 | MNKD | -2.32 | 9.20 | 9.67 |
| 2025-03-31 | MNKD | -2.32 | 9.08 | 9.67 |
| 2025-04-01 | MNKD | -2.32 | 9.08 | 9.67 |
| 2025-04-02 | MNKD | -2.32 | 9.08 | 9.67 |
| 2025-04-03 | MNKD | -2.32 | 9.08 | 9.67 |
| 2025-04-04 | MNKD | -2.32 | 9.08 | 9.67 |
| 2025-04-07 | MNKD | -2.36 | 9.18 | 9.66 |
| 2025-04-08 | MNKD | -2.36 | 9.18 | 9.66 |
| 2025-04-09 | MNKD | -2.36 | 9.18 | 9.66 |
| 2025-04-10 | MNKD | -2.36 | 9.18 | 9.69 |
| 2025-04-11 | MNKD | -2.37 | 9.18 | 9.69 |
| 2025-04-14 | MNKD | -2.37 | 9.20 | 9.69 |
| 2025-04-15 | MNKD | -2.37 | 9.20 | 9.69 |
| 2025-04-16 | MNKD | -2.37 | 9.20 | 9.69 |
| 2025-04-17 | MNKD | -2.37 | 9.20 | 9.69 |
| 2025-04-18 | MNKD | -2.37 | 9.20 | 9.69 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.03
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
0.07
Insider Transactions
-2.37
Institutional Transactions
9.2
Beta
1.17
Average Sales Estimate Current Quarter
76
Average Sales Estimate Next Quarter
79
Fair Value
7.15
Quality Score
39
Growth Score
79
Sentiment Score
35
Actual DrawDown %
40.5
Max Drawdown 5-Year %
-57.3
Target Price
10.25
P/E
49.62
Forward P/E
17.75
PEG
1.05
P/S
4.83
P/B
P/Free Cash Flow
42.55
EPS
0.09
Average EPS Est. Cur. Y
0.27
EPS Next Y. (Est.)
0.32
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
9.66
Relative Volume
0.67
Return on Equity vs Sector %
-55
Return on Equity vs Industry %
-41.6
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
0.27
EBIT Estimation
MannKind CorporationSector: Healthcare
Industry: Biotechnology
Employees: 403
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
stock quote shares MNKD – MannKind Corporation Stock Price stock today
news today MNKD – MannKind Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch MNKD – MannKind Corporation yahoo finance google finance
stock history MNKD – MannKind Corporation invest stock market
stock prices MNKD premarket after hours
ticker MNKD fair value insiders trading